Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2021-10-29 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
中源协和细胞基因工程股份有限公司独立董事关于关联交易事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent director's opinion on a related party transaction, referencing regulatory guidelines and company governance rules. It discusses the fairness and legality of a specific transaction and the board's approval process. The content is a formal opinion or statement related to governance and compliance rather than a full report or announcement of financial results. It does not contain financial statements or detailed financial data, nor is it a notice of voting results or a proxy solicitation. It fits best under Regulatory Filings (RNS) as a compliance-related disclosure that does not fit other specific categories.
2021-10-29 Chinese
中源协和细胞基因工程股份有限公司关于控股子公司与天津市红磡物业经营管理有限公司签署物业服务委托合同暨关联交易的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding a related party transaction involving a property management service contract between the company's subsidiary and an affiliated company controlled by the company's actual controller. It includes contract terms, pricing, service scope, and board approval details. There is no financial statement or report data, nor is it a transcript, presentation, or regulatory certification. The document is a formal announcement of a related party transaction, which is a typical regulatory filing to inform shareholders and the market about significant related party dealings. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Report. It is not a voting result or a capital change announcement. Given the nature and content, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2021-10-29 Chinese
中源协和细胞基因工程股份有限公司2021年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2021 年第三季度报告" which translates to "2021 Third Quarter Report." It contains detailed financial data including income statements, balance sheets, cash flow statements, and notes on accounting changes. The report covers the period of the third quarter of 2021 and includes unaudited financial statements. The presence of comprehensive financial data and analysis for a period shorter than a full fiscal year indicates this is an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial statements, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2021-10-29 Chinese
中源协和细胞基因工程股份有限公司关于签署参股公司合源生物科技（天津）有限公司股权购买权特别协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Zhongyuan Xiehe Cell Gene Engineering Co., Ltd. regarding the signing of a special agreement on the purchase rights of equity in a jointly invested company, Heyuan Biotechnology (Tianjin) Co., Ltd. It details the terms of the agreement, the background, risk control measures, and the impact on the listed company. The document is a formal announcement of a corporate transaction related to equity purchase rights and investment agreements, not a financial report, earnings release, or regulatory certification. It does not contain financial statements or detailed financial data but rather describes the terms and implications of the agreement. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2021-10-29 Chinese
中源协和细胞基因工程股份有限公司关于续聘会计师事务所的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the reappointment of an accounting firm (信永中和会计师事务所) as the company's auditor for the year 2021. It details the firm's qualifications, independence, audit fees, and the approval process by the board and independent directors. There are no financial statements or audit results included, only information about the appointment process and the auditor's credentials. The document length is 2451 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document is best classified as an Audit Report / Information announcement related to auditor appointment, which fits the category AR (Audit Report / Information).
2021-10-29 Chinese
中源协和细胞基因工程股份有限公司独立董事关于续聘信永中和会计师事务所为公司2021年度审计机构的独立意见
Audit Report / Information Classification · 95% confidence The document is an independent opinion from the independent directors regarding the reappointment of an audit firm (信永中和会计师事务所) as the company's auditor for the 2021 fiscal year. It references compliance with governance codes and company bylaws, and confirms the audit firm's qualifications and independence. The document is short (725 characters) and does not contain actual financial statements or audit results, but rather an opinion on the audit firm's reappointment. This fits the category of an Audit Report / Information (AR) as it relates to audit matters but is not a full annual report or financial statement. Therefore, the classification is AR with high confidence.
2021-10-29 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.